DPd against DVd for daratumumab-naïve patients with R/R multiple myeloma

TRIMM-2: talquetamab + daratumumab in patients with R/R multiple myelomaПодробнее

The impact of daratumumab on the myeloma treatment landscapeПодробнее

Treatment options for patients with multiple myeloma who are resistant to daratumumabПодробнее

IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myelomaПодробнее

Updates: DPd treatment in patients with R/R myelomaПодробнее

MRD negativity rates in t(11;14) R/R multiple myeloma following treatment with VenDd or DVdПодробнее

Approval of Dvd for myeloma at first relapse in the UK: impacts on careПодробнее

Daratumumab Plus VRd for Multiple Myeloma | NEJMПодробнее

Multiple Myeloma Stories: Relapsed/Refractory MM Patient Shares Daratumumab, Elotuzimab ExperienceПодробнее

Darzalex (daratumumab) - 2024 Updated #myelomaПодробнее

Mechanism of action & use of daratumumab in multiple myelomaПодробнее

GMMG-DANTE: DVd in patients with multiple myeloma and renal impairmentПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

Treatment approach for multiple myeloma with CNS relapseПодробнее

Daratumumab in combination with carfilzomib and dexamethasone for relapsed multiple myelomaПодробнее

Daratumumab: Revolutionizing the Fight Against Multiple MyelomaПодробнее

Rapid daratumumab infusion for MMПодробнее

25 years of Myeloma UK: Daratumumab approved because patients are heardПодробнее

Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairmentПодробнее